Add this topic to your myFT Digest for news straight to your inbox
Xi Jinping hopes manufacturing can offset the property slump
Moderna alleges Pfizer and BioNTech infringed its patents in use of mRNA platform
Shah Capital wants change in US biotech’s strategy as its shares have tumbled since their pandemic peak
Pledges to invest in pandemic preparedness with facility in Kenya fall short as sales of Covid jabs decline
Not only is the cost-benefit ratio unbeatable, but not to undertake this spending is to court disaster
Officials warn weaknesses in surveillance will hinder vaccine development as countries struggle to agree accord
We risk forgetting the lessons of the Covid pandemic
‘Brain fog’ detectable in long and short-term cases, detailed study suggests
Discovery boosts efforts to develop ‘biomarkers’ for debilitating condition and enable treatments
Fears condition’s range of symptoms and link to chronic diseases will have lasting impact on health systems
Pharma companies, while talking up pipelines, are turning to deals to boost their growth outlook
Better awareness and access are needed to rebuild measles vaccination rates
A trial of $3 payments for getting a Covid jab in rural Ghana offers a game-changing way to meet public health goals
Millions of Paxlovid pills have gone unused as tight controls restrict access
Americans’ interest in vaccinations has flagged despite efforts to boost uptake of latest jab
Company would have been better off following Roche’s route to market for anti-obesity treatment
Vaccine recipient claims he suffered side effect of severe blood clot
Covid may have abated, but emerging diseases and new drug categories are keeping the analytics firm busy
German group slashes guidance by €1bn and reduces spending as it expects fewer first vaccine doses and lower boosting
Biotech blames weaker US sales after lowering full-year forecast
Call for rapid detection comes as pharma groups criticise draft WHO treaty on how to avoid another health crisis
Biotech group hit by lower demand, with majority of write-offs relating to raw materials bought during pandemic
US biotech has been struggling to overcome fall in demand for coronavirus jabs
Doubts grow over safety and effectiveness of drugs that were marketed as coronavirus treatments
Combined jab as effective as separate shots in early stage tests
International Edition